Anti-allodynic efficacy of Botulinum neurotoxin a in a model of neuropathic pain
Anti-allodynic efficacy of Botulinum neurotoxin a in a model of neuropathic pain
复制标题
DOI：
10.1016/j.neuroscience.2006.12.004
复制
发表时间：
2007-03-02
期刊：
影响因子：
3.3
通讯作者：
Pavone, F.
中科院分区：
文献类型：
--
作者：
Luvisetto, S.;Marinelli, S.;Pavone, F.
神经性疼痛的典型特征是周围和中枢神经系统损伤，其原因包括癌症、糖尿病、多发性硬化症、带状疱疹后神经痛、身体创伤或手术等。患有神经性疼痛的患者对非甾体抗炎药的常规治疗没有反应，并且对阿片类药物的敏感性降低，通常与严重的副作用相关。最近，已证明 A 型肉毒神经毒素 (BoNT/A) 能够在炎性疼痛病症中诱导镇痛。本研究的目的是测试 BoNT/A 是否也能够缓解神经性疼痛症状。通过使用坐骨神经的慢性收缩损伤（一种神经性疼痛的小鼠模型），我们观察到外周给予 BoNT/A 可以强烈减少与这种神经病相关的机械性异常性疼痛。值得注意的是，单次无毒剂量的 BoNT/A 足以诱导抗异常疼痛作用，且持续至少 3 周。这一结果尤其重要，因为目前的药物疗法对神经性疼痛的治疗效果不佳。此次交流扩大了我们对 BoNT/A 在改善人类健康状况方面的潜在新医学用途的认识，对于开发针对神经性疼痛的新药物治疗方法具有非常重要的意义。 (c) 2006 年国际广播组织。由爱思唯尔有限公司出版。保留所有权利。
Neuropathic pain is typified by injuries to the peripheral and central nervous system and derives from such causes as cancer, diabetes, multiple sclerosis, post-herpetic neuralgia, physical trauma or surgery, and many others. Patients suffering neuropathic pain do not respond to conventional treatment with non-steroidal anti-inflammatory drugs and show a reduced sensitivity to opiates often associated with serious side effects. Recently, it has been demonstrated that botulinum neurotoxin serotype-A (BoNT/A) is able to induce analgesia in inflammatory pain conditions. The goal of this research was to test if BoNT/A was able to relieve also neuropathic pain symptoms. By using chronic constriction injury of the sciatic nerve, a mouse model of neuropathic pain, we observed that peripheral administration of BoNT/A strongly reduced the mechanical allodynia associated with this neuropathy. Remarkably, a single non-toxic dose of BoNT/A was sufficient to induce anti-allodynic effects, which lasted for at least 3 weeks. This result is particularly relevant since neuropathic pain is poorly treated by current drug therapies. This communication enlarges our knowledge on potentially new medical uses of BoNT/A in efforts to ameliorate human health conditions, with very important implications in the development of new pharmacotherapeutic approaches against neuropathic pain. (c) 2006 IBRO. Published by Elsevier Ltd. All rights reserved.